"Sun Pharmaceuticals Generics Company Intelligence Report" now available at Fast Market Research

Feb. 13, 2011 - PRLog -- India-based Sun Pharmaceutical Industries was established in 1983, initially selling psychiatry-related products in West Bengal and Bihar. Sun has grown to be an international company with 17 manufacturing locations and a presence in 30 countries.

Group companies include the US-based Caraco Pharmaceutical Laboratories, in which Sun holds a majority stake. Caraco had sales of over US$337 million in 2008/09, but has faced regulatory issues in 2009 which has led to products being seized by the FDA.

Sun has a strong presence in cardiology, diabetes and neurology.

Sun reported annual sales in FY2008/09 worth Rs42,723 million (US$932.2 million), with total revenues worth Rs44,808.1 million (US$977.7 million). This was an increase over the prior year of 27% and 28%, respectively. Profit after tax reached Rs18,177.3 million (US$396.6 million), up by 22% over the prior year.

Since the middle of 2007, Sun has been in a battle to acquire the Israel-based Taro Pharmaceutical Industries. The effort has become increasingly bitter, and has been heard in Israel's Supreme Court. Sun finally won control of Taro in September 2010.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/121465_sun_pharmaceuticals_gen...


Report Table of Contents:

Executive Summary
Introduction
Group Companies
Caraco Pharmaceutical Laboratories
Sun Pharmaceutical Industries (SPI)
Sun Pharmaceutical (Bangladesh)
Alkaloida Chemical Company Exclusive Group Ltd
Taro Pharmaceutical Industries
Products
Sun withdraws EU repaglinide marketing authorisation application
Sun Pharmaceutical Laboratories ANDA Approvals, January 2002 - September 2010
Recent product approvals
Diltiazem (US)
Desloratadine (US)
Carbidopa / levodopa / entacapone (US, tentative)
Rosuvastatin (US, tentative)
Riluzole (US, tentative)
Venlafaxine ER (US)
Tamsulosin (US)
Rivastigmine (US)
Azelastine (US)
Alprazolam (US)
Levetiracetam (US)
FDA approves memantine?
Bupropion hydrochloride (US)
Promethazine hydrochloride and codeine (US)
Oxaliplatin (US)
Docetaxel (EU)
Atomoxetine (US, tentative)
Nicardipine (US)
Imatinib (US, tentative)
Ketorolac (US)
Sumatriptan (US)
Oxaliplatin (US)
Bicalutamide (US)
Azelastine (US, tentative)
Financial results
Latest Quarterly Results, Q211
Sun Pharmaceutical Industries: Consolidated Quarterly Results, in Rs millions
Sun Pharmaceutical Industries: Consolidated Quarterly Results, in US$ millions
Latest Yearly Results, FY2009/10
Sun Pharmaceutical Industries: Consolidated Fiscal Year Results, in Rs millions
Sun Pharmaceutical Industries: Consolidated Fiscal Year Results, in US$ millions
Major developments
Sun Pharma receives warning letter from the FDA
Sun Pharma plans to enter Japanese generic sector
Litigation
Sun sees gemcitabine patent victory against Eli Lilly
Nycomed and Pfizer see pantoprazole litigation success
Forest / Merz settle memantine litigation
Rosuvastatin patent upheld in court
Sun settles carbidopa / entacapone / levodopa and entacapone litigation
Court ruling ends Sun's oxaliplatin sales
Sun gains gemcitabine litigation success
Forest and Lundbeck enter escitalopram settlement with Sun and Caraco
Contact Details

About Espicom Business Intelligence

Espicom Business Intelligence is a highly-regarded and established provider of business intelligence services. Founded in 1982 as MDIS Publications Ltd, the company changed its name to Espicom in 1992. Initially a publisher in a wide range of industries such as power generation and telecommunications, they now focus on the global pharmaceutical and medical device sectors.  View more research from Espicom Business Intelligence at http://www.fastmr.com/catalog/publishers.aspx?pubid=1025

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.